ES2311464T3 - Terapia con variante de lipoproteina lipasa (lpl). - Google Patents

Terapia con variante de lipoproteina lipasa (lpl). Download PDF

Info

Publication number
ES2311464T3
ES2311464T3 ES00943499T ES00943499T ES2311464T3 ES 2311464 T3 ES2311464 T3 ES 2311464T3 ES 00943499 T ES00943499 T ES 00943499T ES 00943499 T ES00943499 T ES 00943499T ES 2311464 T3 ES2311464 T3 ES 2311464T3
Authority
ES
Spain
Prior art keywords
lpl
therapeutic
protein
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00943499T
Other languages
English (en)
Spanish (es)
Inventor
Michael R. Hayden
John J. P. Kastelein
Katherine Julia Diane Ashbourne Excoffon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Amsterdam Molecular Therapeutics AMT BV
Original Assignee
University of British Columbia
Amsterdam Molecular Therapeutics AMT BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Amsterdam Molecular Therapeutics AMT BV filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2311464T3 publication Critical patent/ES2311464T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
ES00943499T 1999-06-24 2000-06-23 Terapia con variante de lipoproteina lipasa (lpl). Expired - Lifetime ES2311464T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202048 1999-06-24
EP99202048 1999-06-24

Publications (1)

Publication Number Publication Date
ES2311464T3 true ES2311464T3 (es) 2009-02-16

Family

ID=8240356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00943499T Expired - Lifetime ES2311464T3 (es) 1999-06-24 2000-06-23 Terapia con variante de lipoproteina lipasa (lpl).

Country Status (12)

Country Link
US (1) US20110201673A1 (enExample)
EP (1) EP1200117B1 (enExample)
JP (1) JP5095894B2 (enExample)
AT (1) ATE404217T1 (enExample)
AU (1) AU5799200A (enExample)
CA (1) CA2370081C (enExample)
CY (1) CY1108511T1 (enExample)
DE (1) DE60039880D1 (enExample)
DK (1) DK1200117T3 (enExample)
ES (1) ES2311464T3 (enExample)
PT (1) PT1200117E (enExample)
WO (1) WO2001000220A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044960B1 (en) * 2004-03-02 2013-11-20 Cellectar, Inc. Phospholipid analogue for the in vivo diagnosis of cancers
WO2005123117A1 (en) * 2004-06-21 2005-12-29 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of non alcoholic steatotic hepatitis (nash)
EP1945779B1 (en) 2005-10-20 2013-03-06 UniQure IP B.V. Improved aav vectors produced in insect cells
CN101506369B (zh) 2006-06-21 2014-02-12 尤尼克尔生物制药股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav-rep78翻译起始密码子的载体
BRPI0814459B1 (pt) 2007-07-26 2023-01-24 Uniqure Ip B.V Método para produzir um vírion parvoviral recombinante em uma célula de inseto, e, construção de ácido nucleico
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2432497A1 (en) * 2009-05-18 2012-03-28 Amsterdam Molecular Therapeutics (AMT) IP B.V. Use of lipoprotein lipase (lpl) in therapy
DK3708192T3 (da) 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
WO2011112089A2 (en) 2010-03-11 2011-09-15 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Mutated rep encoding sequences for use in aav production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
AU2013216920B2 (en) 2012-02-07 2016-09-22 Global Bio Therapeutics, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
MX385339B (es) 2014-03-10 2025-03-18 Uniqure Ip Bv Vectores aav mejorados adicionales producidos en células de insecto.
MA41035A (fr) 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
US12123030B2 (en) 2016-05-18 2024-10-22 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
AU2017378191A1 (en) 2016-12-16 2019-07-04 Uniqure Ip B.V. Immunoadsorption
PL3652326T3 (pl) 2017-07-10 2025-02-24 Uniqure Ip B.V. Środki i sposoby terapii genowej aav u ludzi
CN111183225B (zh) 2017-07-20 2023-11-17 优尼科Ip有限公司 在昆虫细胞中改进的aav衣壳产生
WO2019129859A1 (en) 2017-12-29 2019-07-04 Uniqure Ip B.V. Modified viral vectors and methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755268A1 (en) * 1994-04-11 1997-01-29 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
US5658729A (en) * 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Also Published As

Publication number Publication date
DE60039880D1 (en) 2008-09-25
JP2003503355A (ja) 2003-01-28
CY1108511T1 (el) 2014-04-09
CA2370081C (en) 2014-06-03
JP5095894B2 (ja) 2012-12-12
EP1200117B1 (en) 2008-08-13
PT1200117E (pt) 2008-11-26
CA2370081A1 (en) 2001-01-04
ATE404217T1 (de) 2008-08-15
DK1200117T3 (da) 2008-11-17
WO2001000220A2 (en) 2001-01-04
WO2001000220A3 (en) 2001-07-12
AU5799200A (en) 2001-01-31
EP1200117A2 (en) 2002-05-02
US20110201673A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
ES2311464T3 (es) Terapia con variante de lipoproteina lipasa (lpl).
Cheng et al. Identification and characterization of VPO1, a new animal heme-containing peroxidase
ES2684349T3 (es) Péptidos y composiciones para el tratamiento de daños de las articulaciones.
EP0998307B1 (en) METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF
CA2216878A1 (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
US20110081332A1 (en) Treatment of non-alcoholic steatotic hepatitis (nash)
EP3609577B1 (en) Brown fat-selective adipokines
WO2020176732A1 (en) TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY
US9290751B2 (en) LPL variant therapeutics
CN107073078A (zh) 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物
EP2059122B1 (en) Methods and compositions related to apobec-1 expression
FI120154B (fi) Yhdistelmä-DNA-viruksia, niitä sisältävä farmaseuttinen koostumus, niillä tartutettu nisäkässolu ja soluja sisältävä istute
US20190134223A1 (en) Methods and compositions for treating heart failure
Signori et al. ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice
US20070134229A1 (en) Non-native constitutively active osteopontin
WO2024159175A2 (en) Compositions, systems, and methods for reducing adipose tissue
WO2025169974A1 (ja) 遺伝子発現を駆動する制御配列、当該制御配列と作動可能に連結されたａｔｍ遺伝子を含む構築物、および当該構築物を含むアデノウイルスベクター
AU747449B2 (en) Recombinant viruses, preparation and use thereof in gene therapy
ES2252032T3 (es) Modulacion de angiogenesis usando angiotensina-7 antiangiogenica y polinucleotidos codificantes para dicha sustancia para el tratamiento de tumores.
JP2006519873A (ja) 血管形成を促進するための腫瘍内皮マーカー１、９、および１７の使用
Cronican Macromolecule Delivery Into Mammalian Cells Using Supercharged Proteins
KR20030081187A (ko) 엘아이피에 대한 엘에이피 비율 조절방법